SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced its decision on the following therapies:

ACCEPTED FOR USE

  • Xolair (omalizumab) as add-on therapy in severe persistent allergic asthma.
  • Januvia (sitagliptin) for treatment of type II diabetes mellitus in combination with metformin.
  • Budenofalk (budesonide) for ulcerative colitis of the rectum and sigmoid colon.
  • Invanz (ertapenum) for prophylaxis of surgical site infection following elective colorectal surgery.
  • Atimos Modulite (formoterol) for coronary obstructive pulmonary disease.

REJECTED FOR USE

  • Cipralex (escitalopram) for obsessive compulsive disorder.
  • Prialt (ziconotide) for treatment of severe, chronic pain.
  • Cystadane (betaine) as adjunctive treatment of homocystinuria.

Further information: The Scottish Medicines Consortium

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases